Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2026-03-24 Report Publication Anno…
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program
Report Publication Announcement Classification · 1% confidence The document is a brief immediate report under Regulation 4 of the Israeli Securities Regulations referencing a Form 6-K filing (“Attached hereto is a report on 6k 6k24032026_isa.pdf”). It runs under 2,000 characters and merely announces that the actual 6-K report is attached. Under the “Menu vs Meal” rule, such short notices announcing an attached report are classified as Report Publication Announcements (RPA), not the report itself.
2026-03-24 English
Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in AgeRelated Primary Moderate-to-Severe Knee Osteoarthriti
Regulatory Filings Classification · 1% confidence The document is a Form 6-K filing by a foreign private issuer (Enlivex Ltd.) with the SEC, reporting a press release on FDA clearance of an IND application. It is not a full annual or interim report, earnings release, management discussion or other specialized report, but rather a regulatory submission under the Exchange Act. Therefore, it falls under the generic “Regulatory Filings” category (RNS).
2026-03-23 English
Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in AgeRelated Primary Moderate-to-Severe Knee Osteoarthriti
Report Publication Announcement Classification · 1% confidence The document is an Immediate Report under Israeli Securities Regulations 4, stating “Attached hereto is a report on 6k” and referencing an attached PDF (Form 6-K). It does not contain the report’s content itself but is simply announcing the publication of the report. Under the “menu vs meal” rule, this is a Report Publication Announcement.
2026-03-23 English
Immediate Report
Capital/Financing Update Classification · 1% confidence The document is a 'Prospectus Supplement' filed pursuant to Rule 424(b)(5) of the Securities Act of 1933. It details an 'at-the-market' offering of ordinary shares, which relates to capital raising and financing activities. According to the provided definitions, documents related to fundraising and financing updates fall under the 'CAP' category.
2026-03-21 English
Immediate Report
Report Publication Announcement Classification · 1% confidence The document is an 'Immediate Report' filed with the Israel Securities Authority (MAGNA system). It explicitly states 'Attached hereto is a report on ENLIVEX Prospectus Supplement' and provides a filename for the attachment. Following the 'Menu vs Meal' rule, since this is a short notification announcing the availability of an attached document rather than the document itself, it is classified as a Report Publication Announcement (RPA).
2026-03-21 English
FORM 3-INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES-Pomerantz Roger
Director's Dealing Classification · 1% confidence The document is a Form 3 filed with the SEC, which is an 'Initial Statement of Beneficial Ownership of Securities'. This form is used by directors, officers, and beneficial owners to report their holdings in a company's securities. In the provided classification schema, reports of personal share transactions or holdings by company directors and executives are categorized as 'Director's Dealing' (DIRS).
2026-03-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.